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ABSTRACT 
Botulinum neurotoxins (BoNTs) and tetanus neurotoxin (TeNT) are the most potent toxins known 
and cause botulism and tetanus, respectively. BoNTs are also widely utilized as therapeutic toxins. 
They contain three functional domains, responsible for receptor-binding, membrane translocation, 
and proteolytic cleavage of host proteins required for synaptic vesicle exocytosis. These toxins 
also have distinct features: BoNTs exist within a progenitor toxin complex, which protects the 
toxin and facilitates its absorption in the gastrointestinal (GI) tract, whereas TeNT is uniquely 
transported retrogradely within motor neurons. Our increasing knowledge of these toxins has 
allowed the development of engineered toxins for medical uses. The discovery of new BoNTs and 
BoNT-like proteins provides additional tools to understand the evolution of the toxins and to 
engineer toxin-based therapeutics. This review summarizes the progress on our understanding of 
BoNTs and TeNT, focusing on the progenitor toxin complex, receptor recognition, new BoNT-
like toxins, and therapeutic toxin engineering. 
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INTRODUCTION 
The concept of bacterial toxins was first proven in 1888 by Emile Roux and Alexandre Yersin, 
who demonstrated that bacterial culture filtration is sufficient to reproduce the disease diphtheria 
in animal models (1), proving that a biochemical entity released from bacteria was the major 
disease-causing agent. It is now well established that bacterial toxins act as “guided missiles” to 
target and disrupt specific physiological functions in animals and humans. Many of them reach the 
cytosol of the target cells and modify specific cellular components. These intracellular-acting 
toxins evolved as multi-domain proteins with distinct modes of actions and diverse cellular targets. 
Identification and characterization of these bacterial toxins led to development of vaccines using 
de-activated toxins (known as toxoids), which constituted one of the major medical triumphs of 
the 20th century in preventing some of the most devastating infectious diseases. In addition, a 
mechanistic understanding of bacterial toxins has enabled their utilization as scientific tools and 
therapeutic proteins, taking advantage of their evolutionarily-refined ability to modulate specific 
cellular functions.  
  
The most potent toxins target the nervous system and are termed neurotoxins. The focuses of this 
review, botulinum neurotoxins (BoNTs) and tetanus neurotoxin (TeNT), claim the top positions 
as “the most potent toxins known” (2). They are the causative agents of two distinctive diseases: 
botulism and tetanus, respectively. Tetanus has been a major infectious disease throughout human 
history. Identification of TeNT led to the development of effective vaccines, and immunization 
has now largely eliminated tetanus from developed countries. In contrast to tetanus, botulism is a 
rare disease in humans. Thus, the general population is not vaccinated against BoNTs. This lack 
of immunity allows BoNTs to be used as therapeutic toxins for treating a growing list of medical 
conditions as well as for cosmetic purposes (3, 4). At the same time, this lack of immunity leaves 
society vulnerable to the potential use of BoNTs in bioterrorism attacks. Thus, BoNTs are 
classified as one of the most dangerous bioterrorism agents (5).  
 
BoNTs are traditionally classified into seven serotypes (BoNT/A-G), while TeNT has only a single 
type (6, 7). Serotyping is a classical way to distinguish biologics, based on whether polyclonal 
anti-sera induced by one entity can recognize/neutralize a second entity. All BoNTs and TeNT 
belong to the same toxin family, known as clostridial neurotoxins. These toxins share the same 
molecular architecture and are produced in bacteria as a ~150 kDa pro-toxin with three functional 
domains (Figure 1A). The N-terminal domain is designated the light chain (LC, ~50 kDa). The 
other two domains constitute the heavy chain (HC, ~100 kDa). The LC is a zinc-dependent 
protease. The HC is the delivery vehicle, with an N-terminal domain (HN, ~50kDa) responsible for 
delivering the LC into the cytosol and a C-terminal domain (HC, ~50 kDa) responsible for 
recognizing specific cell-surface receptors. The HC further contains two sub-domains, including 
an N-terminal HCN and a C-terminal HCC. A short linker region between the LC and HC needs to 
be cleaved by either bacterial or host proteases in order to convert the pro-toxin into its active form. 
The LC and HC remain connected via an inter-chain disulfide bond until the LC reaches the cytosol, 
where the disulfide bond is reduced and the LC is released into the cytosol of neurons. The full-
length structures of BoNT/A, B, E, and TeNT have been determined (Figure 1B) (8-11). BoNT/A 
and BoNT/B have a similar linear arrangement of the three domains with their HCs isolated from 
the LCs, while the HC and LC are located on the same side of the HN in BoNT/E and TeNT, with 
interactions between all three domains. Additionally, there is a “belt” extending from the HN that 
surrounds the LC (Figure 1B), which potentially occupies the same cleft as the substrate proteins. 
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This tri-modular structure underlies the mode of action for BoNTs and TeNT: they target and enter 
motor nerve terminals at neuromuscular junctions (NMJs) via receptor-mediated endocytosis. 
Acidification of the endosome triggers conformational changes of the toxins that result in transfer 
of the LC across endosomal membranes into the cytosol, where the LC blocks neurotransmitter 
release from nerve terminals by cleaving a specific set of proteins known as SNARE (Soluble N-
ethylmaleimide-sensitive factor Attachment protein Receptor) proteins. These proteins, including 
more than 60 members in mammalian cells, constitute the core complex that mediates membrane 
fusion events in eukaryotic cells (12-14). BoNTs and TeNT specifically cleave the set of SNARE 
proteins that mediate fusion of synaptic vesicle membranes to the pre-synaptic membrane in 
neurons, including the plasma membrane protein syntaxin 1, the peripheral membrane protein 
SNAP-25, and vesicle membrane proteins VAMP1, 2, and 3 (Figure 2A). The seminal discovery 
of SNARE proteins as the substrates for BoNTs and TeNT in the early 1990’s, led by Giampietro 
Schiavo and Cesare Montecucco (6, 15), coincides with the groundbreaking work from James 
Rothman’s laboratory on the purification of the SNARE complex (16), and provided pivotal 
evidence for establishing the central role of the SNARE complex in mediating membrane fusion.  
 
Tremendous progress has been made in understanding the biology and mode of action of BoNTs 
and TeNT in recent years, as described in several recent excellent reviews (6, 7, 17-19). Here we 
aim to provide an up-to-date discussion on our current understanding of BoNTs and TeNT. 
 
BOTULISM AND THE BONT PROGENITOR COMPLEX  
Botulism is usually caused by food poisoning (food-borne) due to ingesting food containing 
BoNTs (7). These toxins are produced by a variety of anaerobic spore-forming Clostridial species 
categorized as Clostridium botulinum, and also include strains known as C. baratii, C. butyricum, 
and C. argentinensis. These bacteria are ubiquitous throughout the world. There are frequent 
botulism outbreaks in wild animals, while the incidence of botulism among humans has become 
rare. Besides being a food-borne disease, botulism can also be caused by colonization of the 
intestine by C. botulinum. This usually occurs in infants before their normal gut microbiota is fully 
developed and is known as infant botulism. C. botulinum can also colonize wounds in rare cases 
and causes wound botulism. The typical symptom of botulism is flaccid paralysis – the inability 
to contract skeletal muscles. The first sign is usually impaired vision, as muscles controlling eye 
movement are affected. This is followed by paralysis of facial muscles and ultimately patients die 
due to respiratory failure caused by diaphragm paralysis.   
 
Food-borne botulism is unique in that it is caused by ingesting the toxin, rather than live bacteria. 
This oral route posts a formidable challenge for a protein toxin, as it has to remain intact while 
passing through the gastrointestinal (GI) tract. To meet this challenge, BoNTs are produced and 
exist as part of a protein complex called the progenitor toxin complex (PTC), which is encoded 
within a single gene cluster. Immediately preceding the bont gene is another gene encoding a 
protein termed NTNHA (also known as NTNH) (nontoxic nonhemagglutinin protein). BoNTs and 
NTNHAs form heterodimers, which constitute the minimal PTC (M-PTC). Crystal structures of 
the M-PTC from BoNT/A and BoNT/E have been determined (20, 21), showing that NTNHA and 
BoNT form a tight complex resembling interlocked hands that bury a large surface area and renders 
BoNTs resistant to low pH and proteases (Figure 3). BoNT-NTNHA interactions drastically 
change the position of the HC, and the interactions of this domain with NTNHA are critical in the 
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formation of the complex. BoNT-NTNHA interactions are pH-dependent; for instance, the M-PTC 
of BoNT/A is stable at pH 6.5, but disassembles at pH 7.5, providing a mechanism to release the 
toxin after passing the GI tract.   
 
Besides NTNHA, a BoNT gene cluster always contains one of two sets of genes: (1) an HA cluster 
that encodes three hemagglutinin proteins termed HA17, HA33, and HA70 based on their 
molecular weights; or (2) an OrfX cluster that encodes the proteins OrfX1, OrfX2, OrfX3 and P47. 
Remarkable advancements have been achieved in understanding the function and structure of the 
HA proteins, which form a complex that binds to the M-PTC to make the large progenitor toxin 
complex (L-PTC, ~ 760 kDa). Negative staining electron microscopy (EM) revealed the overall 
domain arrangement of the native L-PTCs of BoNT/A (L-PTC/A), BoNT/B, and BoNT/D (22-
24), showing that the HA proteins form a large triskelion complex, with the NTNHA-BoNT 
complex bound on top of it (Figure 3). The crystal structure of the recombinant HA complex of 
BoNT/B revealed a triskelion-shaped structure with each arm forming a “Y” shape, composed of 
two HA33, one HA17, and one HA70 (25). The crystal structures of two sub-components of the 
HA complex of BoNT/A were also determined (23). One is the central hub formed by three HA70; 
the other is the extended arm composed of a part of HA70 in complex with a HA17 and two HA33 
(termed mini-HA). The assembled HA of BoNT/A was docked into negative stain EM density of 
the native L-PTC/A, revealing that the interactions between the M-PTC and the HA complex are 
mediated by a flexible loop in NTNHA, termed the nLoop, which binds to HA70.  
 
Two major functions of the HA complex have been established. Firstly, the HA complex mediates 
multi-valent binding to cell surface carbohydrates. The crystal structure of HA70 in complex with 
sialyllactose and the HA17-HA33 in complex with galactose, lactose, or LacNAc have been 
determined, showing that HA70 and HA33 each contain one carbohydrate binding site (23). In 
total, each HA complex contains 9 carbohydrate-binding sites. It was recently shown that 
carbohydrate binding mediates the enrichment of the HA of BoNT/A to glycoprotein 2 (GP2) on 
the microfold cells (M-cells) of the intestine (26). GP2 mediates transcytosis of microbes and 
particles from the intestinal lumen to the lamina propria across M-cells, as a way to expose foreign 
antigens to immune cells. Thus, the carbohydrate-binding capability of HA may contribute to the 
initial absorption of L-PTC/A through M-cells. Consistently, mice lacking M-cells or GP2 showed 
reduced susceptibility to oral feeding of L-PTC/A. 
 
Secondly, the HA complex is capable of disrupting cell-cell junctions. Utilizing the HA complex 
of BoNT/B as a bait, Sugawara et al identified E-cadherin as a specific binding partner for HA 
(27). It was subsequently shown that the HA complex of BoNT/A also recognizes E-cadherin (28). 
E-cadherin is a member of the cadherin family that mediates cell-cell adhesions. E-cadherin is 
found mainly in epithelial cells and contains five tandem extracellular cadherin (EC) domains 
(EC1 to EC5). HAs of BoNT/A and BoNT/B recognize the terminal EC1-EC2 fragment. The 
crystal structure of a mini-HA of BoNT/A in complex with the EC1-EC2 fragment of E-cadherin 
has been determined (28), revealing that interactions involve binding to EC1 by HA70, interactions 
of both EC1 and EC2 to HA17, and a small hydrophobic interface between EC1 and one of HA33. 
EC1 is the domain that mediates trans-dimerization between two E-cadherin molecules on 
neighbouring cells, which mediates cell-cell adhesion. Binding of HA to EC1 blocks trans-
dimerization of E-cadherin, thus disrupting cell-cell adhesions and opening up a paracellular route 
for absorption of BoNTs. As E-cadherin is distributed on the basolateral side of intestinal epithelial 
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cells, it would be necessary for some L-PTC to be able to cross the intact epithelial barrier initially. 
Carbohydrate-binding-mediated transcytosis through M-cells might contribute to this initial 
process.  
 
The physiological relevance of both the carbohydrate-binding and E-cadherin interactions for the 
oral potency of BoNT/A has been demonstrated by Lee et al, who succeeded in reconstituting the 
complete L-PTC/A using proteins purified recombinantly in E. coli (28). This approach allowed 
them to create L-PTC/A containing point mutations in HA that specifically disrupted either 
carbohydrate binding or E-cadherin binding. Both mutant forms of L-PTC/A showed reduced oral 
toxicity compared to wild-type (WT) L-PTC/A in mice.  
In addition, it has been reported that the HA complexes of BoNT/C and D can cause vacuoles in 
cells and induce cell death, although the physiological relevance of this observation remain to be 
established (29). In contrast to HA, the function of the OrfX proteins remains unknown. In strains 
with the OrfX gene cluster, only the M-PTC has been isolated. It remains unclear whether OrfX 
proteins may form complexes with each other or with the M-PTC, although weak interactions have 
been observed using mass spectrometry (30). Crystal structures of recombinantly expressed OrfX2 
and P47 have been determined, revealing that both proteins contain domains with a tubular lipid-
binding (TULIP) fold (31, 32). These structural features suggest that P47 and OrfX2 might have 
lipid-binding capabilities, and OrfX1 and OrfX2 have been shown to bind phosphatidylinositol 
phosphate lipids (31).  
 
RECOGNITION OF PRESYNAPTIC NERVE TERMINALS 
Once BoNTs enter the circulatory system, they target pre-synaptic motor nerve terminals. The 
lethal dose for mice with intraperitoneal injection of BoNTs ranges from 0.1 ng to 1 ng/Kg, making 
BoNTs the most potent toxins known (2). Lethality from such a low toxin concentration results 
from the extreme specificity with which it targets neurons. To meet these challenges, BoNTs have 
evolved a strategy of recognizing two distinct classes of receptors simultaneously. One set of 
receptors are abundantly expressed on neuronal surfaces and interact with BoNTs with relatively 
low affinity. The second set of receptors then firmly anchors the toxin on nerve terminals and leads 
to endocytosis of the toxin (Figure 4A). This “double-receptor” model was first proposed by 
Cesare Montecucco in 1986 and is now well-established for the majority of BoNTs (33).  
 
Ganglioside Receptors 
The first set of receptors identified for BoNTs and TeNT are complex gangliosides, a class of 
glycosphingolipids composed of a ceramide tail, and a carbohydrate headgroup with various 
numbers of sialic acids attached. There are more than 60 ganglioside species, and different cell 
types express distinct profiles of gangliosides. The carbohydrate headgroups and sialic acids of 
gangliosides extend from the cell surface and are utilized as attachment points for various ligands, 
viruses, and bacterial toxins. The complex forms of gangliosides, which contain an additional N-
acetylgalactosamine (GalNAc) and galactose (Gal) in their headgroups compared to the simple 
form of gangliosides, are abundant on neuronal membranes. Binding of BoNTs and TeNT to 
complex gangliosides were reported in the 1960-1970’s (34, 35). In recent years, the physiological 
relevance of complex gangliosides as receptors for BoNTs and TeNT have been established 
 6 
utilizing knockout (KO) mouse lines lacking different enzymes required to synthesize all or partial 
lines of complex gangliosides, which showed reduced susceptibility to BoNTs and TeNT (36-45).  
 
Binding of BoNTs and TeNT to complex gangliosides has been well characterized in vitro. A 
ganglioside binding site (GBS) with the conserved core residues SxWY was initially mapped to 
the C-terminal tip of the HCC of TeNT (HCC/T) (46). This GBS was further confirmed for the HC 
of BoNT/A (HC/A) and BoNT/B (HC/B), and is conserved in BoNT/A, B, E, F, and G (47, 48). 
The crystal structures of TeNT (full-length and HC/T), BoNT/A (HC/A), BoNT/B (HC/B), and 
BoNT/F (HC/F) in complex with the carbohydrate headgroups of complex gangliosides have been 
determined (11, 46, 49-52), revealing that the GBS recognizes mainly the GalNAc-Gal moiety, 
together with sialic acids, thus providing a structural basis for the toxins’ selectivity toward 
complex gangliosides.  
 
The SxWY motif is not conserved in BoNT/C and D, but there is clear in vivo evidence that 
BoNT/C and D require complex gangliosides as receptors (37, 44). Mutagenesis studies suggest 
that the position in BoNT/C and D analogous to the conserved GBS in other BoNTs may contribute 
to ganglioside-binding (41, 42). HCs of BoNT/C (HC/C) and BoNT/D (HC/D) also contain an 
additional sialic-acid-binding site, termed Sia-1 in BoNT/C. Mutations within the Sia-1 site reduce 
toxin binding to gangliosides, suggesting that BoNT/C and D may contain a second ganglioside-
binding site at this position. TeNT also contains a sialic-acid-binding site (also termed “R” site) at 
the analogous region to the Sia-1 site (46, 47, 53, 54). Mutations at this site reduced binding of 
TeNT to complex gangliosides, suggesting that TeNT contains two ganglioside-binding sites. 
However, under physiological conditions, whether the second ganglioside binds to the Sia-1 site 
on neuronal surfaces remains to be established.  
BoNT/DC is a naturally existing chimeric toxin evolutionarily related to BoNT/C and D. Its LC 
and HN are almost identical to BoNT/D, while its HC (HC/DC) shares ~77% identity to HC/C (55). 
The SxWY motif is not conserved in HC/DC. BoNT/DC is unique among all BoNTs in that its 
binding and entry are not affected in cultured neurons lacking complex gangliosides, and the 
toxicity of BoNT/DC in mice lacking complex gangliosides is similar to that in WT mice (45). 
The crystal structure of HC/DC in complex with the terminal components of a complex ganglioside 
head group revealed that HC/DC recognizes carbohydrates at a site analogous to the conserved 
GBS of other BoNTs (Figure 4C), but HC/DC only recognizes the sialic acid moiety and does not 
interact with the carbohydrate backbone. Therefore, BoNT/DC is able to utilize a wide range of 
sialic-acid-containing surface molecules as receptors. As gangliosides are the major sialic-acid-
containing molecules, accounting for ~65% of the total sialic acids in neuronal plasma membranes, 
neurons lacking gangliosides still showed greatly reduced levels of binding and entry of BoNT/DC.  
 
Protein Receptors – Synaptotagmin I and II 
Nishiki et al first identified two homologous synaptic vesicle membrane proteins, synaptotagmin 
(Syt) I and II, as BoNT/B binding partners in the 1990’s (56, 57). Later studies established that 
Syt-I and Syt-II are functional protein receptors that mediate binding and entry of BoNT/B into 
cells (58). Subsequently, BoNT/G and BoNT/DC were also reported to utilize Syt-I and -II as 
functional receptors (38, 59, 60). Syt-I and -II are single spanning transmembrane proteins, with a 
C-terminal cytoplasmic domain and a short N-terminal tail inside the vesicle lumen (Figure 4A). 
Syt-I/II are key synaptic vesicle membrane proteins and their cytoplasmic domain functions as the 
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Ca2+ sensors for triggering synaptic vesicle exocytosis (61). Using Syt-I/II as receptors suggests 
an entry pathway for BoNTs (Figure 4A): these proteins are usually hidden inside neurons within 
synaptic vesicles. When neurons are active and releasing neurotransmitters, the luminal tail of Syt-
I/II becomes transiently exposed on cell surfaces and available for toxin binding. Neurons actively 
recycle Syt-I/II to regenerate synaptic vesicles, which provides an efficient access route for the 
toxin. This activity-facilitated entry pathway enhances neuronal specificity and enables the toxins 
to preferentially attack active neurons.  
Defining Syt-I and II as the functional receptors for BoNT/B, DC, and G was straightforward, as 
purified recombinant Syt-I and -II luminal fragments directly and specifically bind to all three 
toxins in vitro (57-60). Neurons lacking Syt-I/II become resistant to the above toxins, and 
expression of Syt-I/II restored binding and entry of these toxins (38, 60). The binding sites for 
BoNT/B, G, and DC have been mapped to the same short sequence adjacent to the transmembrane 
domain within the luminal tail of Syt-I/II. The minor residue differences between Syt-I and -II 
within this binding region accounts for their differences in binding affinity toward BoNTs, with 
Syt-II showing higher binding affinity than Syt-I (57, 62, 63). Syt-II is expressed at all motor nerve 
terminals, while Syt-I was only co-expressed in ~40% of motor nerve terminals (64). Thus, Syt-II 
likely acts as the major toxin receptor at NMJs. The physiological relevance of Syt-I and II as toxin 
receptors has been further demonstrated for BoNT/B and BoNT/DC using competition assays: 
recombinant Syt-II fragments containing the toxin-binding site reduced toxicity of BoNT/B and 
DC in vivo in mice (58, 60).  
The crystal structure of BoNT/B in complex with Syt-II was determined in 2006 in two parallel 
studies (62, 65). The structure revealed that the Syt-II fragment binds to a hydrophobic groove in 
the HCC of BoNT/B (Figure 4B). The binding is mainly mediated by hydrophobic interactions, 
particularly through the key residues F47 and F54 in Syt-II. Multiple other interactions influence 
the binding specificity and affinity. F47 and F54 are highly conserved in Syt-II across a wide range 
of vertebrate species, but humans and chimpanzee Syt-II contains an L residue at the F54 position. 
This single residue difference severely reduces binding of BoNT/B, G, and DC to human Syt-II 
compared to mouse/rat Syt-II, which might explain why humans are less sensitive to BoNT/B 
compared to BoNT/A (60, 66).  
The Syt-binding site in HC/B is located close to, but separated from the GBS. The HC of BoNT/G 
(HC/G) shares ~50% sequence identity with HC/B, and the crystal structure of HC/G showed that 
the Syt-binding site is largely conserved (67, 68). In contrast, HC/DC shares a rather low (~33%) 
sequence identity with HC/B. The crystal structures of HC/DC in complex with human Syt-I and 
Syt-II peptides have been determined (69) (Figure 4C). Syt-I and Syt-II are recognized in a similar 
manner, with Syt-I (37-48) and Syt-II (43-54) both forming an amphipathic helix docking into the 
hydrophobic pocket at the C-terminus of HC/DC. Although the key Syt residues involved in 
binding are the same, BoNT/DC presents a distinct Syt-binding site, located perpendicular to the 
Syt-binding site in BoNT/B. Interestingly, the C-terminus of the Syt-II peptides ends up at a similar 
location when bound to either BoNT/B or BoNT/DC, with the rest of Syt-II peptide extending 
perpendicularly. Because the C-terminus is next to the transmembrane domain of Syt-II, both 
toxins would be anchored at a similar position relative to the membrane.  
The relationship between ganglioside-binding and Syt-binding was further clarified by the first 
ternary crystal structure of a HC/B-Syt-ganglioside complex (50) (Figure 4B). The structure 
demonstrated that the GBS and Syt-binding site are isolated from each other, with no significant 
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conformational changes upon simultaneous binding to the two receptors. Thus, the GBS and Syt-
binding site provides two independent anchoring points in the “double-receptor” model.  
Protein receptors – SV2 
As hijacking the synaptic vesicle recycling process appears to be a preferred entry pathway, 
searching for receptors for BoNTs was carried out by systematically screening synaptic vesicle 
membrane proteins. These studies led to the discovery that BoNT/A utilizes another synaptic 
vesicle membrane protein, SV2 (synaptic vesicle glycoprotein 2) as its receptor (70, 71). This is 
consistent with the finding that internalized BoNT/A is largely localized within synaptic vesicles 
(72). BoNT/A is still capable of entering neurons “silenced” by other BoNTs (79). This is possibly 
because synaptic vesicle membrane proteins are initially delivered to the plasma membrane via 
constitutive exocytosis during their biosynthesis, before subsequent endocytosis and sorting into 
synaptic vesicles. Because such a constitutive exocytosis process is not affected by BoNTs, 
BoNT/A is still capable of utilizing SV2 in neurons pre-treated with other BoNTs, albeit at lower 
efficacy. 
SV2 includes three isoforms (SV2A, B, and C) in mammals. SV2A is selectively expressed in a 
subpopulation of motor nerve terminals of slow muscle fibers, while SV2B and SV2C are broadly 
expressed in motor nerve terminals (73). SV2 contains 12 transmembrane helices. Its N-terminus 
and C-terminus are on the cytosolic side. BoNT/A recognizes the fourth luminal domain of SV2 
(SV2-L4) and can utilize all three homologs as its receptors (Figure 4D). The evidence for SV2 as 
a BoNT/A receptor is considerable. First, BoNT/A binds directly and specifically to SV2C-L4 
recombinantly expressed in E.coli and also showed weak binding to SV2A-L4 and SV2B-L4 (70, 
71). Second, binding and entry of BoNT/A into neurons lacking all SV2s are blocked, and can be 
rescued by expression of full-length SV2A/B/C, or a chimeric receptor containing the L4 of 
SV2A/B/C (40, 70). On neuronal surfaces, the three SV2 isoforms are similarly capable of 
mediating binding and entry of BoNT/A. Finally, BoNT/A showed a reduced binding to the NMJs 
of SV2B KO mice and a lower toxicity on SV2B KO mice in vivo compared to WT mice (70). 
The crystal structure of HC/A in complex with human SV2C-L4 expressed in E. coli was 
determined (74). The structure revealed that SV2C-L4 forms a quadrilateral β-helix with 
overlapping β-strands (Figure 4D), a fold similar to pentapeptide repeat proteins. This type of 
architecture is prone to forming higher-order aggregates, similar to the formation of amyloid fibrils. 
HC/A appears to utilize this weakness in this fold and stacks its own β-strands onto the exposed β-
strands of SV2C-L4. The interactions are mainly through backbone-to-backbone hydrogen bonds, 
thus largely depending on recognizing the overall β-strand conformation, rather than specific 
residues. This binding model is in sharp contrast to the BoNT-Syt-I/II interactions, which include 
extensive side-chain interactions that ensure high binding specificity. Another major difference is 
that while the Syt-binding site is located within the HCC, the SV2-binding site involves residues 
from both HCN and HCC. The HC/A structure in the HC/A-SV2C-L4 complex is similar to apo-HC/A, 
suggesting that SV2C binding does not cause any significant conformation change of HC/A.  
The promiscuous nature of backbone-to-backbone interactions is difficult to reconcile with the 
highly specific receptor-recognition of BoNT/A and raises the question of whether additional 
interactions with SV2 are involved. SV2-L4 contains three N-linked glycosylation sites conserved 
across SV2A, B and C. By expressing glycosylation-deficient mutant forms of SV2A in SV2-null 
neurons, it was shown that the first two of the three glycosylation sites did not affect binding and 
entry of BoNT/A. However, removing the third glycosylation site (N573 in SV2A), which is 
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located within the SV2-BoNT/A binding interface, diminished the efficacy of BoNT/A entry into 
neurons, suggesting that glycosylation at this site is critical for high-affinity binding of BoNT/A 
to SV2 (40, 75, 76).  
To understand the role of the N-linked glycan in BoNT/A binding, Yao et al determined the 
structure of HC/A in complex with a glycosylated human SV2C-L4 (75) (Figure 4D). The protein-
protein interface is largely the same as the structure of non-glycosylated SV2C-L4 with HC/A, but 
a complex glycan was clearly observed extending from the third glycosylation site (N559 in SV2C) 
into a pocket of HC/A. The two innermost GlcNAc, the third mannose and a fucose are well defined 
and are recognized through a network of hydrogen bonds and van der Waals interactions. These 
interactions nearly double the binding interface between HC/A and SV2C-L4 from 557Å2 to 925Å2. 
Consistently, binding of HC/A to glycosylated SV2C-L4 showed significantly slower dissociation 
rate compared to its binding to non-glycosylated SV2C-L4 (75, 76). The physiological relevance 
of glycan binding was further established as a mutant BoNT/A containing F953R showed no 
detectable toxicity at mouse diaphragm motor nerve terminals (75). Interestingly, this glycan-
binding site overlaps with the epitope region for a well-established BoNT/A-neutralizing human 
monoclonal antibody (77). The structure of N-linked glycosylation is highly heterogeneous, but 
the base of all N-linked glycans is conserved across species, starting with two GlcNAc and a 
mannose. In essence, BoNT/A utilizes conserved carbohydrate moieties to expand the binding site 
and enhance the specificity and avidity of the BoNT/A-SV2 interactions. This “composite” binding 
model, which combines a backbone-to-backbone-mediated conformation-dependent recognition 
with an invariable post-translational modification moiety, has the advantage of tolerating a high 
degree of residue variations in host species as it does not depend on any specific side-chain 
interactions.  
BoNT/E was also found to utilize SV2 as its functional receptor, as binding and entry of BoNT/E 
into neurons lacking all SV2s are blocked, and can be rescued by expression of full-length SV2A 
or SV2B (but not SV2C), or a chimeric receptor containing the L4 of SV2A or SV2B (40). 
Furthermore, BoNT/E showed lower potency on ex vivo preparation of diaphragm tissues from 
SV2B KO mice and lower toxicity in SV2B KO mice in vivo. Unlike BoNT/A, which can utilize 
all three SV2s, BoNT/E can use only SV2A and SV2B, but not SV2C, at least not in cultured 
hippocampal/cortical neurons (40). Binding of BoNT/E appears to be more dependent on the N-
linked glycan at the third glycosylation site of SV2 than BoNT/A, as mutating the N573 site in 
SV2A completely abolished its function to mediate binding and entry of BoNT/E. Consistently, 
BoNT/E showed no detectable binding to non-glycosylated SV2-L4. Direct binding of HC/E to 
glycosylated SV2A-L4 has been shown, and mutagenesis approaches suggest that the SV2-binding 
site involves the interface region between HCN/E and HCC/E (78). However, the exact interacting 
interface remains to be established. 
BoNT/D has also been shown to utilize all three SV2s as its functional receptors on cultured 
hippocampal/cortical neurons (44). However, direct binding of BoNT/D to SV2 has yet to be 
demonstrated, and the in vivo relevance of SV2 for BoNT/D remains to be validated. Interestingly, 
the binding mechanism of BoNT/D appears to be distinct from BoNT/A and E. Mutating any one 
of the three conserved glycosylation sites in SV2A showed no effect on its ability to mediate 
binding and entry of BoNT/D (44). Furthermore, chimeric receptors containing SV2-L4 could not 
mediate binding and entry of BoNT/D, suggesting that isolated SV2-L4 is not sufficient to mediate 
BoNT/D binding (44).  
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TeNT was also shown to utilize SV2 as its functional receptors in cultured hippocampal/cortical 
neurons (79). Furthermore, TeNT showed reduced toxicity in SV2B KO mice in vivo, suggesting 
that SV2B contributes to TeNT entry at NMJs in vivo. However, direct interactions of TeNT with 
any SV2s remains to be established. Similar to BoNT/D, mutating any one of the three conserved 
N-linked glycosylation sites does not affect binding and entry of TeNT mediated by SV2A, and 
SV2-L4 in chimeric receptors cannot mediate binding and entry of TeNT. Besides SV2, it has been 
reported that TeNT may interact with extracellular matrix proteins nidogens (80). Two peptides 
derived from two nidogen family members can reduce binding of TeNT to neurons and reduce 
toxicity of TeNT in vivo in mice. Binding of HC/T to NMJs is reduced in the nidogen-2 KO mice, 
and TeNT showed a slightly reduced toxicity in nidogen-2 KO mice. The molecular details of 
TeNT-nidogen interactions and the physiological role of this interaction remain to be further 
elucidated. 
Whether BoNT/F and BoNT/C have their own protein receptors is not clear. BoNT/F has been 
reported to bind glycosylated SV2s (41, 81). However, entry of BoNT/F into SV2 KO 
hippocampal/cortical neurons is at levels similar to entry into WT neurons, suggesting that SV2 is 
not an essential receptor for BoNT/F (44, 79). It has been reported that BoNT/A may utilize 
fibroblast growth factor receptor 3 as another receptor (82), but its role remains to be confirmed.  
The Lipid binding loop (LBL) 
Besides gangliosides and the protein receptors, the lipid membrane itself could contribute to the 
overall affinity of the toxins for cell surfaces. Chai et al first proposed that an exposed loop of 
BoNT/B, located between the GBS and Syt binding site, is in an ideal position to interact with 
lipid membranes through hydrophobic interactions (62) (Figure 4B). All BoNTs contain such a 
loop, although they differ significantly. For instance, the loops in HC/C and HC/DC are long and 
structurally similar to the loop in HC/B, while the loop in HC/A is significantly shorter, which may 
prevent its interaction with membranes. It has been shown that point mutations at the tip of this 
loop reduced binding of HC/C, HC/D, and HC/DC to gangliosides; thus this loop was initially 
proposed as a potential ganglioside-binding site, termed the ganglioside-binding loop (43, 83-86). 
However, this loop could contribute to ganglioside-binding by interacting with the ceramide lipid 
anchors of gangliosides non-specifically. Indeed, analyzing soluble ganglioside carbohydrate head 
groups revealed that the toxin has far lower affinity for the isolated carbohydrate moiety than 
expected (52), suggesting that the lipid membrane itself could contribute to the apparent affinity 
of the toxins for gangliosides. This question was directly addressed experimentally in a recent 
study, which showed that HC/DC is capable of binding to ganglioside-free liposomes in liposome 
floatation assays, and point mutations at the tip of the HC/DC loop abolish this ganglioside-
independent binding to liposomes, demonstrating that this loop binds to lipids in a ganglioside-
independent manner (Figure 4C) (45). A recent study also examined the role of this loop using 
nanodiscs with both gangliosides and Syt embedded within a membrane environment (87). 
Although direct binding of HC/B, HC/DC, and HC/G to immobilized nanodiscs containing lipid 
alone was not detectable under these assay conditions, they found that deletions at the tip of the 
loop reduced binding of these HCs to nanodiscs containing gangliosides alone, Syt-II alone, or a 
combination of gangliosides plus Syt-II. Furthermore, point mutations and deletion of residues at 
the tip of this loop reduced the toxicity of BoNT/B, DC, and G (87), demonstrating a critical role 
of this loop in the potency of these toxins. 
RETROGRADE TRANSPORT OF TeNT 
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The sequence and structure of the TeNT is highly similar to BoNTs, but the disease tetanus, caused 
by TeNT is drastically different from botulism, and is characterized by periodic hyper-contraction 
of skeletal muscles (termed spastic paralysis). TeNT is produced by Clostridium tetani, where the 
toxin is encoded on a plasmid. There are no other toxin-associated proteins, which is consistent 
with the fact that TeNT does not need to pass the GI tract. Instead, TeNT is produced in situ and 
directly enters the circulatory system when C. tetani spores contaminate deep wounds. TeNT and 
BoNTs both target and enter peripheral motor nerve terminals, but their distinct destination 
determines their symptoms (88): while the LC of BoNTs is released into the cytosol of motor 
neurons, the majority of TeNT is transported retrogradely along the motor neuron axon to the soma 
(Figure 5). TeNT is then released from motor neurons and re-enters connecting inhibitory neurons, 
where the LC/T is finally released into the cytosol and blocks neurotransmitter release. Losing 
inhibitory input leads to hyper-activity of motor neurons, resulting in spastic paralysis.  
The potential retrograde traffic routes for TeNT have been thoroughly discussed in recent reviews 
(88, 89), yet the molecular basis for sorting TeNT into retrograde transport pathways remains a 
mystery. It has been previously assumed that HC/T-receptor interactions govern its retrograde 
sorting. However, this view has been challenged by recent studies. Wang et al. generated a series 
of chimeric toxins by switching different domains of BoNTs with their counterparts in TeNT (90). 
Surprisingly, chimeric toxins containing either HC/T or even the entire HC of TeNT both induced 
flaccid paralysis in mice, suggesting that the HC of TeNT is not sufficient to mediate efficient 
retrograde transport (Figure 5). On the other hand, replacing HCT with HC/A also resulted in a 
chimeric toxin that induced flaccid paralysis. These data suggest that HC/T is required but not 
sufficient to mediate efficient retrograde transport of TeNT. Other parts of TeNT including its LC 
are required for efficient sorting. These results are consistent with the observation that TeNT 
showed a low degree of co-localization with HC/T in cells and neurons, and a much higher 
retrograde transport efficacy than HC/T (91-93). The crystal structure of TeNT was recently 
determined, revealing a unique domain arrangement in a closed conformation (Figure 1B), and a 
pH-mediated domain rearrangement between closed and open conformations (11). The exact 
contribution of such domain rearrangements to retrograde sorting of TeNT remains to be 
examined.  
Interestingly, the distinction between TeNT and BoNTs in terms of retrograde sorting is not 
absolute. It has been shown that TeNT induces flaccid paralysis at relatively high toxin 
concentrations (94), suggesting that it can escape from endosomes within motor nerve terminals 
above a certain dose threshold. On the other hand, retrograde transport of BoNT/A has been 
suggested by the earlier observation that radioactivity was detected in the ventral horn of the spinal 
cord when radiolabeled BoNT/A was injected in the rat gastrocnemius muscle (95). Recent studies 
showed that BoNT/A injected in the superior colliculus caused cleavage of SNAP-25 within rat 
retina, and retrograde transport of BoNT/A occurs in both hippocampal neurons and motor neurons 
(96, 97). Utilizing microfluidic devices that separate the axonal terminal versus soma of neurons, 
Restani et al showed that fluorescence-labeled BoNT/A and BoNT/E were both retrogradely 
transported in cultured motor neurons (98), while Bomba-warczak et al showed that BoNT/A, D, 
and TeNT added into the axonal chamber resulted in cleavage of SNARE proteins in second-order 
neurons that do not have any axons in the soma chamber. Adding neutralizing antibodies blocked 
cleavage of SNARE proteins in second-order neurons, suggesting that these toxins were released 
from the first-order neurons into media before they re-enter the second-order neurons. Bomba-
warczak et al also utilized SV2A/B KO neurons and found that the retrograde transport process of 
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these toxins was not affected (99), suggesting that the retrograde sorting of these toxins is 
independent of their entry receptor SV2. How TeNT and BoNTs are sorted into the retrograde 
transport pathways and the molecular determinants for this sorting process remain to be elucidated.  
 
TRANSLOCATION  
Membranes form a formidable barrier for any toxins acting in the cytosol. The HN of BoNTs and 
TeNT facilitates the translocation of their LCs across endosomal membranes. Presumably, low pH 
induces conformational changes in the HN, leading to its interactions with membranes and eventual 
translocation of the LCs. Once exposed in the cytosol, the disulfide bond connecting the HN and 
the LC is reduced, which is facilitated by the NADPH-thioredoxin reductase-thioredoxin system 
in the cytosol (100, 101).  
The molecular details of the membrane translocation process remain to be established. This 
represents a major question not only for BoNT and TeNT, but also for similar bacterial toxins that 
are produced as single polypeptides, such as diphtheria toxin and C. difficile toxins. Our current 
knowledge on translocation of the clostridial neurotoxins have been thoroughly discussed in 
several recent reviews (17, 102), with two major models proposed. One model suggests that HN 
forms a protein transduction channel, which allows unfolded LCs to cross the membrane. 
Consistently, planar lipid bilayer studies and a patch clamp approach revealed that an ion-
conducting channel is formed by the HN (103-105). In this model, formation of a HN channel is a 
prerequisite for LC translocation and the LCs do not contact the lipid membrane. An alternative 
model proposes that the LCs and HN are induced into a “molten globule” state in the presence of 
both low pH and negatively charged lipid membranes. The molten globule state is a partially 
unfolded state that exposes hydrophobic regions of the protein, enabling interactions with the 
hydrophobic core of lipid membranes. In this model, the LC is part of the protein complex exposed 
to lipids. This is supported by earlier studies showing that both the HC and the LC of BoNTs and 
TeNT are labeled by photoactive lipid labeling in model membranes (106, 107). An ion-conducting 
channel might still be formed by the HN in this model during or after translocation of LCs. 
Elucidating the molecular details of the translocation process remains a challenging task and would 
require further development of reconstitution models and structural approaches. 
THE LIGHT CHAIN AND SNARE PROTEIN CLEAVAGE  
The LCs of BoNTs and TeNT act as zinc-dependent proteases in the cytosol of neurons. BoNT/A, 
C, and E cleave SNAP-25. BoNT/B, D, F, G and TeNT cleave VAMP1, 2, and 3 (Figure 2A). In 
addition, BoNT/C also cleaves syntaxin 1. Cleavage of any of the three SNARE proteins is 
sufficient to block formation of SNARE complexes, thus preventing synaptic vesicle exocytosis. 
Blocking synaptic transmission appears to be the only physiologically relevant function of BoNTs 
and TeNT. In addition, high concentrations of BoNT/C and BoNT/E can induce death of cultured 
neurons (108, 109). This is because syntaxin 1 and SNAP-25 are both required for additional 
membrane fusion events, including essential plasma membrane recycling processes in neurons, 
independent of their roles in mediating synaptic vesicle exocytosis (109). This neuronal 
cytotoxicity only occurs when the concentrations of BoNT/C and E reach a level that can cleave 
the majority of syntaxin 1 and SNAP-25 in neurons, which is far higher than the lethal dose of 
these BoNTs.  
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Although the LCs share only approximately 30% sequence identity across all serotypes, this 
domain presents a highly conserved fold, belonging to the M27 family of metalloproteases in the 
MEROPS database (110). The core structure of the LC remains largely unchanged, whether as a 
single domain or as part of the full-length toxin. An open catalytic pocket with surrounding 
negative surface potential generally provides access to the LC active sites. The strictly conserved 
HExxH…E motif presents a typical tetrahedral architecture around the Zn2+ ion that involves the 
His/Glu/His triad and a fourth, water-mediated coordination to the second glutamic acid. This 
water molecule delivers the nucleophile base required for proteolysis. In addition, R362 and Y365 
of BoNT/A were demonstrated to be involved in stabilization of the reaction’s transition state and 
are also conserved across all CNTs (111).   
LCs are proteases with strong specificity for neuronal SNARE proteins. This specificity is the 
result of a complex mechanism of toxin-substrate interaction that involves multiple recognition 
sites (112). This binding mechanism was illustrated by the X-ray crystal structure of LC/A in 
complex with SNAP-25, which defined two exosites (α- and β-) on LC/A that interact with SNAP-
25 (Figure 2B)(113). The structures of LC/F bound to VAMP-derived peptide inhibitors also 
showed key exosites (114). Variation in the composition and localization of the LC exosites seem 
to govern which SNARE proteins can be cleaved, as well as the position of their cleavage sites.  
Residue changes in SNARE proteins render some vertebrate species resistant, or less susceptible, 
to cleavage by BoNTs. For instance, among homologous VAMP1, 2, and 3, rat VAMP1 contains 
a residue change at the BoNT/B and TeNT cleavage site and rats are resistant to both toxins. 
Human VAMP1 contains a change compared to mice at a key residue (position 48), with residue 
I in humans and residue M in mice. This location is critical for binding of LC/D, and the presence 
of an isoleucine reduces the cleavage efficacy of LC/D and renders humans less sensitive to 
BoNT/D (115, 116). A survey of 17 major primate species revealed frequent residue changes in 
VAMP1 at position 48, with either M or I (116). Although these M/I changes could be random and 
neutral events, their effect on the sensitivity to BoNT/D suggests this toxin could have exerted 
selective evolutionary pressure.  
Intriguingly, LC/A has the extraordinary ability to maintain its activity within neurons for several 
months (117, 118). This is a key pharmacological property and underlies its success as a 
therapeutic toxin. Two mechanisms have been proposed. First, LC/A interacts with the 
cytoskeleton component septin, which might sequester LC/A within stable cytoskeleton structures 
underneath the plasma membrane (119). Consistently, motifs at the C-terminus of LC/A have been 
shown to be essential for both binding to septin and for its long half-life in vivo (119-121). The 
details of the LC/A-septin interactions remain to be established at the structural level. Second, it 
has been shown that the C-terminal part of LC/A is able to recruit the deubiquitinating enzyme 
VCIP135/VCPIP1, thus actively inhibiting its degradation by the proteasome (122). In contrast, 
LC/E is rapidly degraded in neurons, potentially via its association with TRAF2, a RING finger 
protein that promotes the ubiquitin-proteasome pathway (123). Consistently the paralysis caused 
by BoNT/E showed a much shorter duration than that caused by BoNT/A (124, 125).  
NEW SEROTYPES, SUBTYPES, AND BoNT-LIKE TOXINS 
BoNTs are traditionally classified based on their distinct serological properties. Recent progress 
in sequencing toxin genes has begun to reveal a growing number of subtypes within the same 
serotype, defined by significant levels of protein sequence differences (2.6% - 31.6%)  (126, 127) 
(Figure 6). They are designated with an Arabic number (e.g. BoNT/A1-A8) and can vary 
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significantly in their activity; for example BoNT/F5 cleaves VAMP1 at a novel site, distinct from 
the canonical site for BoNT/F (128).  
In 2013, a strain isolated from an infant botulism patient expressed both BoNT/B and a novel 
BoNT that cannot be effectively neutralized by standard anti-sera assays (129, 130). The novel 
BoNT was initially designated serotype H. However, genomic sequencing revealed that this 
BoNT/H could also be considered a chimeric toxin (BoNT/FA), with its LC similar to the LC of 
BoNT/F5 and its HC similar to the HC of BoNT/A1 (131). Its toxicity can be neutralized by 
antibodies against the HC of BoNT/A1, although higher concentrations of antibodies are required 
than the standard assays (131).  
Discovering and defining new bacterial toxins are traditionally disease-centric. Rapidly 
accumulating microbial genomic information has however begun to reveal novel toxin genes that 
were not previously directly linked to diseases. In 2015, the genome of C. botulinum strain 111, 
which was originally isolated from an infant botulism patient, was sequenced. This strain is known 
to express BoNT/B2 encoded on a plasmid, and the toxicity of its culture can be neutralized by 
anti-sera against BoNT/B (132). Surprisingly, a novel BoNT gene cluster exists in its genome, 
encoding a typical BoNT (denoted BoNT/X), NTNHA and the OrfX proteins (133). The LC of 
BoNT/X (LC/X) cleaves VAMP1/2/3 at a site distinct from the known cleavage sites for all other 
BoNTs. Interestingly, LC/X is also capable of cleaving other VAMP family members, including 
VAMP4, VAMP5, and Ykt6, although the physiological relevance of cleaving these non-canonical 
substrates remains to be examined. BoNT/X is practically not toxic to mice. This is likely because 
its HC does not recognize mouse/rat neurons effectively. Linking the LC-HC of BoNT/X with 
HC/A resulted in a chimeric toxin with much higher toxicity than when linked to HC/X (133).  
Following the discovery of BoNT/X, another BoNT-like toxin was recently identified in the 
genome of Enterococcus faecium (134). The strain was isolated from cow feces. Genomic 
sequencing revealed a complete BoNT-like gene cluster located on a conjugative plasmid, 
containing a BoNT-like toxin gene, a NTNHA-like gene, and OrfX-like genes. This represents the 
first BoNT-like gene cluster found outside the Clostridium genus. This toxin is denoted as 
BoNT/En (also known as eBoNT/J (135)). BoNT/En and BoNT/X are on the same emerging 
branch in the family tree and share significant (37%) sequence identity (Figure 6). Functional 
characterization revealed that LC/En cleaves VAMP1/2/3 at a novel site (134). Interestingly, 
LC/En is also capable of cleaving SNAP-25 in neurons, although its cleavage of recombinant 
SNAP-25 in vitro is not efficient. The cleavage site is located on the N-terminal half of SNAP-25, 
which is distinct from all known BoNT cleavage sites (134). Similar to BoNT/X, HC/En appears 
unable to recognize mouse/rat neurons, since BoNT/En is not effective in cultured neurons or in 
mice, while linking the LC-HN of BoNT/En with HC/A generates a potent toxin capable of 
targeting neurons and inducing paralysis in mice (134).  
A distantly related BoNT-like toxin gene was also discovered by bioinformatical analysis in the 
genome of bacterium Weissella oryzae, designated BoNT/Wo (136, 137). This potential toxin 
showed only ~14-16% sequence identity with other BoNTs, while the normal range for members 
of the BoNT family is >28%. It lacks the conserved inter-chain disulfide bond, and there is no 
typical BoNT gene cluster associated with BoNT/Wo, although a neighboring gene showed a low 
degree of similarity to NTNHA. BoNT/Wo was reported to cleave rat VAMP2 at a unique 
tryptophan-tryptophan site (137). However, this cleavage has yet to be confirmed in neurons, and 
the physiological relevance of this activity towards rat VAMP2 remains to be determined. 
 15 
BoNT/Wo likely represents a distant relative of BoNTs. BoNT-like toxin domains have also been 
discovered in other species and metagenomic data (138). It is likely that these BoNT-like toxins 
may not target humans/animals, but rather other organisms that have attracted little attention in the 
past. For instance, insects represent one of the largest biomasses in nature, whether these emerging 
toxins target insects remains an intriguing question (139).  
 
TOXIN ENGINEERING  
Clinical use of BoNTs is a great example of turning natural toxins into useful therapeutics. It began 
from the collaborations between Dr. Allen Scott, an ophthalmologist who was seeking non-
surgical methods to weaken overactive muscles, and Dr. Edward Schantz, a microbiologist who 
studies BoNTs (3, 4). Experiments were first carried out on monkeys and later in humans, showing 
that BoNT/A is safe and effective in weakening muscles. BoNT/A is now widely used for treating 
a growing list of medical conditions, including muscle spasms, chronic pain, overactive bladder, 
as well as for cosmetic purposes. BoNT/B is also approved for medical uses. There are two key 
pharmacological properties that make BoNTs ideal therapeutic proteins. First, because only a 
minute amount of toxin is needed to attenuate the activity of target neurons, patients usually do 
not generate neutralizing antibodies even after repeated injections over many years. Second, 
because the effects of BoNT/A last over 3-6 months in humans, a single injection is sufficient to 
maintain the therapeutic effect for months.  
 
With the ever-expanding medical uses of BoNTs, further improvements of the pharmacological 
properties of BoNTs, such as higher efficacy, lower immunogenicity, longer duration, and faster 
onset time, are highly desired. For instance, enhancing the efficacy of BoNTs would reduce the 
amount of toxins needed for injection, thus decreasing the risk of generating neutralizing 
antibodies and adverse diffusion of toxins. Furthermore, longer duration of therapeutic effects is 
particularly beneficial for medical applications that require invasive procedures such as the 
treatment of overactive bladder.  
 
Improvement of toxin activity can be made through point mutations in HC, HN, and LC of BoNTs. 
Mutagenesis studies have been carried out on both HC/A and HC/B to enhance their binding to 
gangliosides and protein receptors, with the rationale that enhancing the receptor-binding step 
would increase the efficacy of the toxin to target and enter human neurons. Crystal structures of 
toxin-receptor complexes provide a solid knowledge basis for structure-based mutagenesis 
approaches. A recent successful example addressed the reduced binding of WT BoNT/B to human 
Syt-II, which contributes to the observed lower potency of BoNT/B in patients. Tao et al carried 
out a mutagenesis screen in HC/B and identified mutations that enhance binding of BoNT/B to 
human Syt-II (140). The engineered toxin showed approximately 11-fold higher efficacy in 
blocking neurotransmission compared to WT BoNT/B on cultured neurons expressing human Syt-
II. Another example is that mutations in the GBS of BoNT/A that enhance its interactions with 
gangliosides also increased the potency of BoNT/A (U.S. Patent 9234011B2) (141). Enhancing 
LC activity has also been explored. For instance, a single mutation (S201P) significantly increased 
the catalytic activity of LC/B on VAMP in vitro (142). However, full-length BoNT/B containing 
this mutation did not present any advantage over WT BoNT/B in multiple cell-based assays or in 
vivo (143). These results suggest that the rate-limiting step in BoNT efficacy resides in the initial 
neuronal recognition rather than the later intracellular activity. The LC/A has been modified to 
enhance its stability or alter its half-life in neurons (121, 144). The LC of BoNT/C (LC/C) has 
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been modified to maintain cleavage of syntaxin-1, but with diminished SNAP-25 cleavage, which 
served as a useful scientific tool to demonstrate the role of syntaxin 1 for synaptic transmission 
and a potential therapeutic toxin targeting syntaxin 1 (145, 146). Modification of the translocation 
process is challenging, as its molecular mechanism remains unknown. Recently, Pirazzini et al 
mutated conserved negatively charged residues in the LC and HN of BoNT/B, based on the 
rationale that protonation of these negatively charged residues is required for the interaction of the 
toxin with the negatively charged membranes (147). They identified a triple mutant that showed 
enhanced activity on hemi-diaphragm models as well as faster onset time, potentially due to 
enhanced translocation efficacy.  
 
The modular structure of BoNT and the variations in activity between serotypes have led to the 
development of chimeric toxins displaying improved pharmacological properties. For example, 
two different studies generated chimeric toxins consisting of the HC/B with the HN+LC domains 
of BoNT/A (90, 148). These recombinant toxins displayed enhanced potency and duration of 
action in mice compared to WT BoNT/A, possibly due to increased binding and entry into neurons, 
as neurons express higher levels of Syt-I/II than SV2s (149).  
 
Besides improving the pharmacological properties of BoNTs, another goal of toxin engineering is 
to expand their use to additional cell types, such as non-neuronal cells and sensory neurons. 
Because the secretion events in these cells may not utilize the same set of SNARE proteins as 
synaptic vesicle exocytosis, alteration/expansion of the substrate selectivity of BoNTs might be 
required. Several attempts have been made to engineer BoNT to cleave SNAP-23, which is 
involved in a number of secretion processes in non-neuronal cells (12). Sikorra et al. recently 
developed a yeast screen-based system to identify the key binding pockets mutations to modify 
LC/A in order to cleave SNAP-23 (150). A single point mutation (K224D) was previously 
identified in LC/E that enables efficient cleavage of both SNAP-25 and SNAP-23 (151). This 
mutant LC/E was capable of degrading SNAP-23 in cultured human epithelial cells and inhibiting 
mucin and interleukin-8 secretion. To target non-neuronal cells effectively, the receptor-binding 
properties of BoNTs need to be altered as well. This can be achieved by replacing the HC to a 
targeting agent that bind specifically to the intended cell types. One example of this approach 
includes fusing the LC+HN of BoNT/D to growth hormone-releasing hormone (GHRH) (152). The 
resulting molecule is effective in inhibiting growth hormone secretion from rat pituitary glands for 
treating pituitary gland related diseases.  
The ability of BoNTs to target motor neurons and deliver their LCs into the cytosol effectively also 
raised interest in utilizing inactive toxins as delivery tools to transport alternative therapeutics into 
motor neurons. For instance, various cargo proteins fused to the N-terminus of BoNT/D can be 
delivered into neurons (153), and inactive BoNT/C has been developed as a vehicle to deliver 
therapeutics into the cytosol of neurons (154). If BoNTs are to be used as delivery tools, their 
toxicity has to be abolished, which is usually achieved by mutating key catalytic residues in LCs. 
However, at high doses, the inactive toxins still induce flaccid paralysis in mice (154). The reason 
for this residual toxicity remains to be elucidated. 
Although clostridial neurotoxins are already the most potent toxin known, our increasing 
understanding of their mechanisms of action has allowed the development of molecules with 
increased potency or altered activity and specificity to meet specific medical needs. The discovery 
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of new toxin serotypes and BoNT-like proteins with analogous functions will provide valuable 
additional tools to engineer toxins with novel pharmacological properties. 
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Figure legends 
Figure 1: 
A: Structure of the botulinum neurotoxin A (PDB 3BTA). The light chain (LC, catalytic domain) 
is shown in cyan, the translocation domain (HN) in blue with the ‘belt’ in purple, and the binding 
domain (HC) in red. The disulfide bond linking light and heavy chains is shown as yellow sticks. 
The zinc ion is shown as a grey sphere. B: The crystal structures of BoNT/B (PDB 1EPW), 
BoNT/E (PDB 3FFZ), and TeNT (PDB 5N0B). Domains are colored as per A, with a schematic 
representation highlighting the domain arrangements in the clostridial neurotoxins. 
  
Figure 2: 
A: Schematic of the SNARE complex membrane fusion event and cleavage sites for 
BoNTs/TeNT. VAMP2 (orange), SNAP-25 (red) and syntaxin 1 (yellow) (PDB 1N7S) form a 
complex that mediates fusion of the vesicular membrane with the presynaptic membrane (lipid 
bilayer in grey) and allows neurotransmitter release (represented as red dots in the synaptic vesicle, 
labelled SV). The structures of the SNARE complex (PDB 1N7S) with VAMP2 (orange), SNAP-
25 (red) and syntaxin 1 (yellow) are enlarged, with the cleavage site for each toxin indicated. It 
should be noted that the toxins cleave their substrate only when in their free form, the complex 
being resistant to proteolysis. B: Structure of the LC/A (cyan) in complex with SNAP-25 (red) 
(PDB 1XTG). The conserved active site residues (HExxH…E) are shown as sticks, with the zinc 
ion as a grey sphere. 
  
Figure 3: 
Structure of the L-PTC/A complex, as described by Lee et al (23). With the M-PTC complex (PDB 
3V0A) made of BoNT/A (LC in cyan, HN in blue and HC in red), and NTNHA (yellow surface), 
and the HA complex composed of HA70 (orange), HA17 (purple) and HA33 (pink) (assembled 
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from PDB 4LO4 and 4LO7).Top left corner is a view from below of the same complex.  
  
Figure 4: 
Dual receptor binding. A: Schematic drawing depicting activity-facilitated binding and entry of 
BoNTs into neurons. (1) Dual-receptor recognition of the presynaptic motoneuron, (2) Receptor-
mediated endocytosis followed by pH-induced conformational change that allows translocation of 
LC in the cytosol, (3) Cleavage of one of the SNARE proteins by LC.  B: BoNT/B (red) binding 
to Syt-II (orange) and ganglioside (dots) from PDB 4KBB. Conserved GBS residues are 
highlighted in cyan, important hydrophobic residues F47 and F54 of Syt are shown as 
sticks.  C: BoNT/DC (red) binding to synaptotagmin 2 (orange) and the sialyl-T antigen (Sial., 
dots) from the superposition of PDB 4ISR and 5LR0, respectively. Residues of the hydrophobic 
loop involved in lipid interaction are shown as sticks (Y1251-W1252-F1253). D: BoNT/A (red) 
binding to gSV2C (yellow) and ganglioside (yellow dots) from the superposition of PDB 5JLV 
and 2VU9, respectively. Conserved GBS residues and F953 are highlighted in cyan. Glycan linked 
to N559 of SV2C are shown as orange dots. The lipid bilayer is represented in grey. Dotted lines 
indicate the continuation of the protein receptors toward their transmembrane domain. 
  
Figure 5:  
Retrograde transport. Schematic representation of the intracellular pathway followed by the 
clostridial neurotoxins. BoNTs mainly act at the neuromuscular junction, while TeNT undergoes 
retrograde transport along the axon and transcytosis to reach the inhibitory interneurons of the 
central nervous system.  
  
Figure 6: 
A phylogenetic split network covering the clostridial neurotoxins and selected homologues, 
illustrates their potential evolutionary relationships, as well as conflicts arising from chimerisms, 
based on their protein sequences (133). The sequences were clustered with UCLUST to 98% 
identity. 
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